On November 4th, futu news reported that a biopharmaceutical company $Viking Therapeutics (VKTX.US)$Today, before the market opens, the stock has surged significantly. As of the time of publication, the stock is up by 23.52%, trading at $90.02, with pre-market trading volume reaching $5.4741 million.

On Sunday, US Eastern Time, Viking announced a research result at the obesity conference: Patients taking 100 mg of VK2735 drug lost 8.2% of their weight after 28 days, which was 6.8% more than patients taking a placebo. According to Viking's report, none of the patients taking the highest dose stopped the medication. The study involved a total of 92 participants who took different doses of this experimental weight loss drug.

Previously, in a report released by Viking in March 2024, patients taking a 40 mg oral dose lost 5.3% of their body weight after 28 days, which was 3.3% more than the placebo group. Compared to $Eli Lilly and Co (LLY.US)$And.$Novo-Nordisk A/S (NVO.US)$Compared to injectable diabetes and weight loss injections, oral medications may be more welcomed by patients.

In addition, Viking also plans to test a new type of weight loss drug, which acts through four different mechanisms. It is worth mentioning that eli lilly and co is also developing a similar multi-target weight loss drug: they are developing a new drug that works through three mechanisms, while their current weight loss drug Zepbound acts through two mechanisms.

About the company

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for metabolic and endocrine disorders. Currently, the company has three compounds in clinical trials.